Keros Therapeutics Inc KROS

Morningstar Rating
$11.28 +1.30 (13.03%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

KROS is trading at a LOCK|#&wM$y premium.
Price
$11.27
Fair Value
LOCK|.jcqc%x
Uncertainty
LOCK|>t <sG$
1-Star Price
LOCK|.Bc<GCL
5-Star Price
LOCK|$mrFzX!
Economic Moat
LOCK|&&
Capital Allocation
—

News

Trading Information

Previous Close Price
$10.03
Day Range
$10.07–11.79
52-Week Range
$8.98–22.50
Bid/Ask
$0.00 / $0.00
Shares Outstanding
19.62M
Market Cap
$221.95M
Volume/Avg
423,306 / 184,947

Key Statistics

Price/Earnings (Normalized)
6.19
Price/Sales
7.50
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
170.32%

Company Profile

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
92

Valuation

Metric
KROS
Price/Earnings (Normalized)
6.19
Price/Book Value
0.80
Price/Sales
7.50
Price/Cash Flow
—
Price/Earnings
KROS

Financial Strength

Metric
KROS
Quick Ratio
17.80
Current Ratio
18.14
Interest Coverage
—
Quick Ratio
KROS

Profitability

Metric
KROS
Return on Assets (Normalized)
−9.79%
Return on Equity (Normalized)
−10.61%
Return on Invested Capital (Normalized)
−12.96%
Return on Assets
KROS

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|&%vZ>GcLOCK|yY?QJ$135B
Regeneron Pharmaceuticals Inc
REGN
LOCK|%^@G&#LOCK|HK$J$99B
Moderna Inc
MRNA
LOCK|!Nkgx%#LOCK|^X$84B
argenx SE ADR
ARGX
LOCK|y<kD?B^LOCK|cDX$59B
BeOne Medicines Ltd ADR
ONC
LOCK|J$#MygLOCK|$RY$48B
Royalty Pharma PLC Class A
RPRX
LOCK|!lCB?kpLOCK|?J<&f$31B
Incyte Corp
INCY
LOCK|tq<^Q#LOCK|bfJ$24B
BioNTech SE ADR
BNTX
LOCK|lFcPs^@LOCK|y%N$21B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|&!ZF^mCLOCK|$yrp!$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|^J$?&sLOCK|z<$15B

Sponsor Center